Marco Valgimigli is associate professor cardiology and senior interventional cardiologist at the Inselspital Universitätsspital Bern. He obtained his medical degree, summa cum laude, from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.
Prof Valgimigli’s areas of research are wide ranging and include high-risk percutaneous interventions (PCI); invasive treatment of myocardial ischaemia (MI); reparative medicine with adult stem cells during MI and heart failure; antithrombotic therapy during and after PCI; and prognostic stratification during acute coronary syndromes and MI.
He serves as national coordinator on numerous clinical trials, including MULTISTRATEGY (Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study), 3T/2R (Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel), PRODIGY (Prolonging Dual Antiplatelet Treatment after Grading Stent-induced Intimal Hyperplasia Study), EXCEL, ZEUS, MATRIX and ODYSSEY.
Prof Valgimigli is a fellow of the European Society of Cardiology, and has been widely published in international journals such as the European Heart Journal, American Heart Journal, Circulation, The Lancet, Journal of the American Medical Association, and The New England Journal of Medicine.
DISCLOSURE: Prof Valgimigli has received research contracts from Iroko Pharmaceuticals, Medtronic, Terumo, and The Medicines Company; has served as a consultant for Abbott, CID (Carbostent & Implantable Devices), Daiichi Sankyo, Eli Lilly, Medtronic, and The Medicines Company; and is on the speaker’s bureaus for Abbott, Accumetrics, AstraZeneca, Daiichi Sankyo, Eli Lilly, Iroko Pharmaceuticals, and Terumo.